IMV

Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical
stage vaccine company, presented positive results from a Phase I/Ib clinical
study of the Company's lead cancer vaccine candidate, DPX-Survivac, this weekend
at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. In a
poster presentation at the conference, Immunovaccine highlighted promising early
evidence of clinical activity for DPX-Survivac in ovarian cancer patients. One
patient, who experienced a 43% reduction in tumor size, was classified as a
partial response (PR) as measured by Response Evaluation Criteria In Solid
Tumors (RECIST 1.1). The PR, which persisted following discontinuation of
treatment, was accompanied by reduction in levels of a commonly used ovarian
cancer biomarker (CA125) and a significant increase in vaccine-induced immune
responses. The patient's tumor and CA125 levels remain stable eight months
following initiation of the DPX-Survivac therapy demonstrating a potentially
durable effect of the therapy. 


Additionally, patients across all vaccine doses exhibited evidence of desired
polyfunctional T cell responses against survivin, a protein that is
over-expressed in ovarian cancer and several other tumor types. Statistically
significant increases in immune response were achieved with higher doses of
DPX-Survivac (p=0.013) and when DPX-Survivac was combined with low dose oral
cyclophosphamide (CPA) (p=0.015). A modified vaccination schedule, reducing the
dose for the first two vaccinations then boosting with a lower dose every eight
weeks, resulted in a lower frequency of local injection related adverse events.
Importantly, robust immune responses were produced with the modified
immunization schedule, demonstrating the potency and flexibility of
DPX-Survivac. Finally, DPX-Survivac was well tolerated with no significant
vaccine related systemic adverse events reported.


"With these latest results, we can for the first time point to the fact that the
pronounced and persistent survivin-specific T cell immune responses we achieve
with DPX-Survivac treatment may translate to a measurable clinical benefit,"
stated Dr. Marc Mansour, chief operating officer of Immunovaccine. "This
connection between immune response and clinical activity is exciting,
particularly since we have demonstrated the ability to generate what we believe
are some of the strongest antigen-specific polyfunctional T cell responses
reported in a clinical trial."


The multicenter Phase I/Ib study enrolled 30 stage IIc-IV first-line or
recurrent ovarian cancer patients with no evidence of disease progression
following chemotherapy. The patients were enrolled across five treatment cohorts
to receive various doses of DPX-Survivac (0.1, 0.25 and 0.5 mL) alone or in
combination with CPA. A modified vaccination schedule was used in two of the
cohorts to evaluate the safety and immune response impact of varying the timing
of treatment. 


"With our ongoing clinical development efforts, we continue to grow our
understanding of the potential role that DPX-Survivac may play in this new
cancer immunotherapy environment. In addition to correlating immune response to
clinical benefit, this study has offered insight into modulating immune response
levels and mitigating adverse events, all through adjusting the vaccine dose and
schedule," said Dr. Mansour. "We are establishing the optimal dosing regimen for
future trials including our planned randomized Phase II trial in ovarian
cancer."


In April, Immunovaccine presented positive data from clinical and preclinical
vaccine studies, including DPX-Survivac, at the American Association for Cancer
Research (AACR) 2014 Annual Meeting. Results demonstrated that metronomic
cyclophosphamide (mCPA), an immune modulating agent, enhanced the immunogenicity
of DepoVax(TM)-based vaccines in preclinical cancer models consistent with
previously reported Phase I data showing a similar enhancement of DPX-Survivac
in patients. Importantly, the animal studies demonstrated the combination
therapy's ability to eliminate advanced tumors that could not be treated with
vaccine or mCPA alone. The addition of anti-PD-1 checkpoint inhibitor to the
DepoVax vaccine/mCPA combination resulted in further enhanced anti-tumor
activity, which allowed the treatment of more advanced tumors. The effective
tumor regressions that were observed could not be achieved without the use of
vaccine or the use of anti-PD-1. 


Immunovaccine expects a large randomized Phase II trial of DPX-Survivac to be
initiated in 2014 in ovarian cancer. The 250 patient trial will be sponsored and
conducted by Canada's NCIC Clinical Trials Group (NCIC CTG). Additionally,
researchers at the University of Rome are planning to initiate a Phase l/II
trial of DPX-Survivac in glioblastoma (brain cancer). 


About DepoVax(TM)

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax platform possesses impressive flexibility, allowing
it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the
DepoVax(TM) adjuvanting platform. Survivin has been recognized by the National
Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of
its therapeutic potential and its cancer specificity. Survivin is broadly
over-expressed in solid tumors and blood cancers including ovarian, breast,
colon and lung cancers, among others. Survivin plays an essential role in
antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting
resistance to various anti-cancer therapies. Survivin is also a prognostic
factor for many cancers and it is found in high percentage of cancer patients.


The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T cell
immune response against cells presenting survivin peptides on HLA class I
molecules. This targeted therapy attempts to use the immune system to actively
search for tumor cells expressing survivin and destroy them. 


About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvants to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax. 


Connect at www.imvaccine.com

This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, is forward-looking information.
Forward-looking statements are based on the estimates and opinions of management
on the date the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual results may differ
materially from those set forth in this press release due to risks affecting the
company, including access to capital, the successful completion of clinical
trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Dr. Marc Mansour
Chief Operating Officer
Immunovaccine Inc.
(902) 492-1819
mmansour@imvaccine.com


Tim Brons
Vida Strategic Partners (media)
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024

(TSXV:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024